WEBULL
News
ASRT
0.7675
-2.12%
-0.0166
Weekly Report: what happened at ASRT last week (1124-1128)?
Weekly Report · 6d ago
Weekly Report: what happened at ASRT last week (1117-1121)?
Weekly Report · 11/24 10:29
Assertio Therapeutics Announces Leadership Change with CEO Resignation
TipRanks · 11/21 22:32
Assertio Holdings CEO Brendan O'Grady Resigns
Reuters · 11/21 22:01
Weekly Report: what happened at ASRT last week (1110-1114)?
Weekly Report · 11/17 10:30
Director David Matthew Stark Reports Disposal of Assertio Holdings Inc. Common Shares
Reuters · 11/12 23:00
Immix Biopharma Appoints Michael Grabow as Chief Commercial Officer
Reuters · 11/12 13:45
Assertio Therapeutics: Strategic Moves and Leadership Changes Drive Buy Rating
TipRanks · 11/12 13:05
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 11/12 12:05
Assertio Therapeutics Reports Strong Q3 Earnings Amid Rolvedon Growth
TipRanks · 11/12 00:08
Lake Street Reaffirms Their Buy Rating on Assertio Therapeutics (ASRT)
TipRanks · 11/11 14:25
Assertio Therapeutics (ASRT) Gets a Buy from H.C. Wainwright
TipRanks · 11/11 11:56
KalVista, Health Catalyst, Bio-Techne Lead After-Hours Gains On Earnings Updates
NASDAQ · 11/11 04:19
Assertio Therapeutics Reports Strong Q3 2025 Results
TipRanks · 11/11 04:01
Assertio narrows 2025 guidance to $110M–$112M as Rolvedon pull-forward shapes cash flow outlook
Seeking Alpha · 11/10 23:22
Assertio (ASRT) Surpasses Q3 Earnings and Revenue Estimates
NASDAQ · 11/10 22:45
Assertio stock rises after revenue beat
Seeking Alpha · 11/10 21:53
Assertio Therapeutics Promotes Paul Schwichtenberg to President
TipRanks · 11/10 21:33
Assertio narrows FY25 product sales view to $110M-$112M from $108M-$118M
TipRanks · 11/10 21:32
Assertio names Paul Schwichtenberg president, COO
TipRanks · 11/10 21:31
More
Webull provides a variety of real-time ASRT stock news. You can receive the latest news about Assertio Holdings Inc through multiple platforms. This information may help you make smarter investment decisions.
About ASRT
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.